Nomination Committee appointed for Diagonal Bio
Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) today announces that the Nomination Committee has been appointed in preparation for the Annual General Meeting (AGM) on May 19, 2026.
According to the instruction for the Nomination Committee adopted by the AGM in 2025, the Nomination Committee for Diagonal Bio’s AGM 2026 shall consist of four members, representing the three largest shareholders on September 30th 2025 together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.
Based on the above, the Nomination Committee for the AGM 2026 has been established to consist of the following persons:
- Anna Frick, represents Svea Bank’s shareholdings, Chairman of the Committee
- Stig Aune, represents own shareholdings
- Lars Moberg, represents Latimo AB’s shareholdings
- Kerstin Jakobsson, Observer, Chairman Diagonal Bio AB
The Company shall publish the names of the Nomination Committee members at least six months before the AGM. If, within two months of the Annual General Meeting, a shareholder’s voting power exceeds that of the shareholder with the fewest votes on the Committee, the new shareholder may request a position, replacing the member with the lowest voting power. The Chairman of the Board convenes the Nomination Committee for a first meeting, at which the Nomination Committee elects a chairman from among its members. The Chairman can participate in the Nomination Committee as an observer.
Shareholders wishing to submit proposals or comments to the Nomination Committee may do so via email to: valberedning@diagonalbio.com. To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than February 28th 2026. The Nomination Committee’s proposals will be presented in the notice convening the AGM and on the Company’s website.
The task of the Nomination Committee prior to the AGM is to prepare and submit proposals regarding the Chairman of the AGM, the number of Board members elected by the AGM, the Chairman and other Board members elected by the AGM, the fees and other remuneration for each of the Board members elected by the AGM and for members of Board committees, the number of auditors, the auditors, the fee for auditors and if applicable new principles for appointing a Nomination Committee, as well as instructions for the Nomination Committee.
The Nomination Committee shall have the right, within a budget approved by the Board, to charge the Company with costs for, e.g., recruitment consultants and other consultants that are required for the Nomination Committee to be able to fulfil its assignment and may also co-opt members to the Nomination Committee if deemed appropriate; co-opted members shall not, however, have the right to vote in the nomination committee. There is no remuneration of the Nomination Committee.
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com
About Diagonal Bio
Diagonal Bio offers a point of care testing system for genetic markers that detects pathogens for viruses, bacteria and fungi. The system is approved for use in animals and current target markets are horses, small animals and fish farms. The Company has expertise in developing markers for eLAMP-testing that can be used on Diagonal’s own system or any other platform using LAMP technology, which creates a potential for licensing and partnerships in the future. Diagonal Bio was founded in 2020, is listed on NGM and headquartered in Lund, Sweden.
